EventsEventsPodcasts
Loader
Find Us
ADVERTISEMENT

EU watchdog mulling authorisation of Merck's anti-COVID pill

FILE: This undated image provided by Merck & Co. shows their new antiviral medication against COVID-19.
FILE: This undated image provided by Merck & Co. shows their new antiviral medication against COVID-19. Copyright Merck & Co via AP
Copyright Merck & Co via AP
By AP with Euronews
Published on
Share this articleComments
Share this articleClose Button

The European Medicines Agency has started reviewing Merck's COVID-19 antiviral treatment, the first pill that has been shown to treat the disease.

ADVERTISEMENT

The European Medicine Agency has "started a rolling review of the oral antiviral medicine molnupiravir" against COVID-19 developed by pharmaceutical company Merck, the agency said on Monday.

If given the green light, it would be the first treatment for coronavirus that does not need to be administered through needles or intravenous infusions.

Earlier this month, Merck asked the US Food and Drug Administration to OK molnupiravir, and a decision is expected within weeks.

The company reported this month that the pill cut hospitalisations and deaths by half among patients with early symptoms of COVID-19. The results were so strong that independent medical experts monitoring the trial recommended stopping it early.

An antiviral pill that people could take at home to reduce their symptoms and speed recovery could prove groundbreaking, easing the crushing caseload on hospitals and helping to curb outbreaks in poorer countries with weak health care systems.

It would also bolster a two-pronged approach to the pandemic: treatment, by way of medication, and prevention, primarily through vaccinations.

Share this articleComments

You might also like

Anti-COVID pill molnupiravir approved for use in the UK in world first for Merck antiviral

In the 'WHO blockade' of Taiwan, everyone is a loser

Scotland's Nicola Sturgeon says she felt 'overwhelmed' by COVID pandemic during testimony